000963 Huadong Medicine Co.,Ltd.
Closed 12-22 15:00:00
40.54
-0.06
-0.15%
High40.74Low40.33Vol3.59M
Open40.60D1 Closing40.60Amplitude1.01%
Mkt Cap71.11BTradable Cap71.07BTotal Shares1.75B
T/O146.00MT/O Rate0.20%Tradable Shares1.75B
P/B2.95ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

China Court Dismisses Huadong Medicine Unit's Copyright Infringement Case
MT Newswires Live  ·  12-15
China Court Dismisses Huadong Medicine Unit's Copyright Infringement Case
Huadong Medicine's Two Drugs Placed in China's Insurance Drug List
MT Newswires Live  ·  12-08
Huadong Medicine's Two Drugs Placed in China's Insurance Drug List
Heidelberg Pharma Appoints Dr. Dongzhou Jeffery Liu as CEO
Reuters  ·  11-24
Heidelberg Pharma Appoints Dr. Dongzhou Jeffery Liu as CEO
Huadong Medicine to Buy Back Restricted Shares for 6.4 Million Yuan
MT Newswires Live  ·  11-24
Huadong Medicine to Buy Back Restricted Shares for 6.4 Million Yuan
Huadong Medicine's Unit Gets Nod for Supplementary Application for Imported Drug
MT Newswires Live  ·  11-18
Huadong Medicine's Unit Gets Nod for Supplementary Application for Imported Drug
Chinese doctors call for insurance coverage for weight-loss drugs
Reuters  ·  11-14
Chinese doctors call for insurance coverage for weight-loss drugs
Huadong Medicine Unit Secures Acceptance of New Drug Application for Topical Cream
MT Newswires Live  ·  11-12
Huadong Medicine Unit Secures Acceptance of New Drug Application for Topical Cream
Huadong Medicine (000963.SZ) Receives NMPA Acceptance for Roflumilast Cream (ZORYVE®) 0.15% Marketing Authorization Application
Stock News  ·  11-11
Huadong Medicine (000963.SZ) Receives NMPA Acceptance for Roflumilast Cream (ZORYVE®) 0.15% Marketing Authorization Application
Chinese Drug Administration Accepts Marketing Application of Huadong Medicine's Unit for Roflumilast Cream; Shares Up 1%
MT Newswires Live  ·  11-03
Chinese Drug Administration Accepts Marketing Application of Huadong Medicine's Unit for Roflumilast Cream; Shares Up 1%
Huadong Medicine's Q3 Profit Rises 8%, Revenue Climbs Nearly 5%
MT Newswires Live  ·  10-28
Huadong Medicine's Q3 Profit Rises 8%, Revenue Climbs Nearly 5%
Huadong Medicine Co.,Ltd. (000963.SZ) Reports Q3 Results: Net Profit Up 7.24% YoY to RMB 2.748 Billion
Stock News  ·  10-28
Huadong Medicine Co.,Ltd. (000963.SZ) Reports Q3 Results: Net Profit Up 7.24% YoY to RMB 2.748 Billion
BRIEF-Huadong Medicine Q3 Net Profit Up 7.7% Y/Y
Reuters  ·  10-27
BRIEF-Huadong Medicine Q3 Net Profit Up 7.7% Y/Y
Huadong Medicine Q3 Net Profit up 7.7% Y/Y
THOMSON REUTERS  ·  10-27
Huadong Medicine Q3 Net Profit up 7.7% Y/Y
Huadong Medicine's Unit Gets Nod to Trial DR10624 Injection in US
MT Newswires Live  ·  10-22
Huadong Medicine's Unit Gets Nod to Trial DR10624 Injection in US
Huadong Medicine Co., Ltd. (000963.SZ): FDA Approves Clinical Trial Application for DR10624 Injection
Stock News  ·  10-21
Huadong Medicine Co., Ltd. (000963.SZ): FDA Approves Clinical Trial Application for DR10624 Injection
Huadong Medicine Gets Approval for Kidney Function Diagnostic Drug
MT Newswires Live  ·  10-20
Huadong Medicine Gets Approval for Kidney Function Diagnostic Drug
Huadong Medicine Co., Ltd. (000963.SZ): Approval Granted for Registration of Remabazine Injection
Stock News  ·  10-17
Huadong Medicine Co., Ltd. (000963.SZ): Approval Granted for Registration of Remabazine Injection
Huadong Medicine Files for Regisration of Dermal Filler
MT Newswires Live  ·  10-17
Huadong Medicine Files for Regisration of Dermal Filler
Huadong Medicine Co., Ltd. (000963.SZ): Registration Application for Lidocaine Injection Cross-Linked Sodium Hyaluronate Gel Accepted
Stock News  ·  10-16
Huadong Medicine Co., Ltd. (000963.SZ): Registration Application for Lidocaine Injection Cross-Linked Sodium Hyaluronate Gel Accepted
Huadong Medicine Unit Gets Clinical Trial Nod for Anti-Tumor Drug
MT Newswires Live  ·  10-10
Huadong Medicine Unit Gets Clinical Trial Nod for Anti-Tumor Drug

Introduction

Company Name.
华东医药股份有限公司
Industry:
零售业
Listing Date:
2000-01-27
Main Business:
　　华东医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是商业、制造业、医美业务。公司凭借优秀的ESG治理能力，WINDESG评级从A级提升至AA级，此外，公司目前MSCIESG评级A级，深交所国证ESG评级AA级，并且获得2024《新财富》杂志“ESG最佳实践”,E药经理人“2025生物医药可持续价值领航奖”等荣誉。
Issue price:
5.76